The program, called DAX Copilot, relieves clinicians from having to enter data into the electronic health record during patient visits and enables them to focus more fully on the patient.

The collaboration will center on the Molecular AI Initiative’s pioneering platform, which uses AI-driven 3D spatial multimodal research to build predictive, high-fidelity models of a patient’s disease at the molecular level.

These new technologies showcase how VUMC researchers are using the power of AI to meet a wide range of medical needs.

In a twist from years past, graduate students and postdoctoral fellows took the helm in selecting the topics and inviting speakers.

VUMC's session will provide a deep dive into how AI-driven 3D spatial molecular and multimodal approaches are transforming the landscape of oncology research.

The approach will address “bottlenecks” that slow the traditional antibody discovery process, and it aims to make it possible to generate monoclonal antibody therapies against any target of interest.

The 12 authors of the recommendations are mainly academics but also include leaders from tech companies Microsoft, Google and Epic.